文献检索文档翻译深度研究
Suppr Zotero 插件Zotero 插件
邀请有礼套餐&价格历史记录

新学期,新优惠

限时优惠:9月1日-9月22日

30天高级会员仅需29元

1天体验卡首发特惠仅需5.99元

了解详情
不再提醒
插件&应用
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
高级版
套餐订阅购买积分包
AI 工具
文献检索文档翻译深度研究
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2025

Assessment of benign tumor burden by whole-body MRI in patients with neurofibromatosis 1.

作者信息

Mautner Victor-F, Asuagbor Florence A, Dombi Eva, Fünsterer Carsten, Kluwe Lan, Wenzel Ralf, Widemann Brigitte C, Friedman Jan M

机构信息

Department of Maxillofacial Surgery, University Hospital Eppendorf, Hamburg, Germany.

出版信息

Neuro Oncol. 2008 Aug;10(4):593-8. doi: 10.1215/15228517-2008-011. Epub 2008 Jun 17.


DOI:10.1215/15228517-2008-011
PMID:18559970
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC2666233/
Abstract

People with neurofibromatosis 1 (NF1) have multiple benign neurofibromas and a 10% lifetime risk of developing malignant peripheral nerve sheath tumors (MPNSTs). Most MPNSTs develop from benign plexiform neurofibromas, so the burden of benign tumors may be a risk factor for developing MPNST. We studied 13 NF1 patients with MPNSTs and 26 age- and sex-matched controls (NF1 patients who did not have MPNSTs) with detailed clinical examinations and whole-body MRI to characterize their body burden of internal benign neurofibromas. Internal plexiform neurofibromas were identified in 22 (56%) of the 39 NF1 patients studied. All six of the NF1 patients with MPNSTs under 30 years of age had neurofibromas visualized on whole-body MRI, compared to only 3 of 11 matched NF1 controls under age 30 (p < 0.05). Both the median number of plexiform neurofibromas (p < 0.05) and the median neurofibroma volume (p < 0.01) on whole-body MRI were significantly greater among MPNST patients younger than 30 years of age than among controls. No significant differences in whole-body MRI findings were observed between NF1 patients with MPNSTs and controls who were 30 years of age or older. Whole-body MRI of NF1 patients allows assessment of the burden of internal neurofibromas, most of which are not apparent on physical examination. Whole-body imaging of young NF1 patients may allow those at highest risk for developing MPNST to be identified early in life. Close surveillance of these high-risk patients may permit earlier diagnosis and more effective treatment of MPNSTs that develop.

摘要

相似文献

[1]
Assessment of benign tumor burden by whole-body MRI in patients with neurofibromatosis 1.

Neuro Oncol. 2008-8

[2]
Association between benign and malignant peripheral nerve sheath tumors in NF1.

Neurology. 2005-7-26

[3]
Benign whole body tumor volume is a risk factor for malignant peripheral nerve sheath tumors in neurofibromatosis type 1.

J Neurooncol. 2014-1

[4]
Longitudinal study of neurofibromatosis 1 associated plexiform neurofibromas.

J Med Genet. 2009-2

[5]
Multimodal Imaging in Neurofibromatosis Type 1-associated Nerve Sheath Tumors.

Rofo. 2015-12

[6]
Association of plexiform and diffuse neurofibromas with malignant peripheral nerve sheath tumor in NF I patients: a whole-body MRI assessment.

Skeletal Radiol. 2024-4

[7]
Atypical neurofibromas in neurofibromatosis type 1 are premalignant tumors.

Genes Chromosomes Cancer. 2011-8-24

[8]
Comprehensive anatomical and functional imaging in patients with type I neurofibromatosis using simultaneous FDG-PET/MRI.

Eur J Nucl Med Mol Imaging. 2018-12-8

[9]
Anatomic and metabolic evaluation of peripheral nerve sheath tumors in patients with neurofibromatosis 1 using whole-body MRI and (18)F-FDG PET fusion.

Clin Nucl Med. 2014-5

[10]
[18F]2-fluoro-2-deoxy-D-glucose positron emission tomography (FDG PET) as a diagnostic tool for neurofibromatosis 1 (NF1) associated malignant peripheral nerve sheath tumours (MPNSTs): a long-term clinical study.

Ann Oncol. 2008-2

引用本文的文献

[1]
Selumetinib Treatment in a Neurofibromatosis Type 1 Child With Second Hit Mutation on the NF1 Gene.

Int J Dev Neurosci. 2025-10

[2]
Surgical Management of a Giant Mediastinal Schwannoma Associated with Neurofibromatosis Type 1: A Case Report.

Surg Case Rep. 2025

[3]
Precision Medicine for Pediatric Glioma and NF1-Associated Tumors: The Role of Small Molecule Inhibitors.

Curr Oncol. 2025-5-15

[4]
From benign neurofibromas to malignant peripheral nerve sheath tumors (MPNST): a gaming among multiple factors.

Cell Oncol (Dordr). 2025-4-2

[5]
Emerging mechanism and therapeutic potential of neurofibromatosis type 1-related nerve system tumor: Advancing insights into tumor development.

Neurooncol Adv. 2025-2-16

[6]
Surgical Treatment and Targeted Therapy for a Large Metastatic Malignant Peripheral Nerve Sheath Tumor: A Case Report and Literature Review.

Life (Basel). 2024-12-12

[7]
Selumetinib for symptomatic, inoperable plexiform neurofibromas in pediatric patients with neurofibromatosis type 1: the first single-center real-world case series in Japan.

Jpn J Clin Oncol. 2025-4-6

[8]
Whole-body MRI-based long-term evaluation of pediatric NF1 patients without initial tumor burden with evidence of newly developed peripheral nerve sheath tumors.

Orphanet J Rare Dis. 2024-11-4

[9]
[Application of multimodal intraoperative neurophysiological monitoring technology in neurofibromatosis type 1 related peripheral nerve tumor surgery].

Zhongguo Xiu Fu Chong Jian Wai Ke Za Zhi. 2024-10-15

[10]
Diagnosis and management of neurofibromatosis type 1 in Arabian Gulf Cooperation Council Region: challenges and recommendations.

Front Oncol. 2024-8-27

本文引用的文献

[1]
[Utility of 18 FDG positon emission tomography in detection of sarcomatous transformation in neurofibromatosis type 1].

Ann Dermatol Venereol. 2007-10

[2]
[18F]2-fluoro-2-deoxy-D-glucose positron emission tomography (FDG PET) as a diagnostic tool for neurofibromatosis 1 (NF1) associated malignant peripheral nerve sheath tumours (MPNSTs): a long-term clinical study.

Ann Oncol. 2008-2

[3]
Value of PET in the assessment of patients with neurofibromatosis type 1.

AJR Am J Roentgenol. 2007-10

[4]
Malignant peripheral nerve sheath tumors (MPNST) in NF1-affected children.

Anticancer Res. 2007

[5]
The genetic predisposition to and histogenesis of neurofibromas and neurofibrosarcoma in neurofibromatosis type 1.

Neurosurg Focus. 2007-6-15

[6]
Malignant peripheral nerve sheath tumors.

Neurosurg Focus. 2007-6-15

[7]
Neurofibromatosis 1 and neurofibromatosis 2: a twenty first century perspective.

Lancet Neurol. 2007-4

[8]
NF1 plexiform neurofibroma growth rate by volumetric MRI: relationship to age and body weight.

Neurology. 2007-2-27

[9]
Clinical manifestations and management of neurofibromatosis type 1.

Semin Pediatr Neurol. 2006-3

[10]
A prospective study of neurofibromatosis type 1 cancer incidence in the UK.

Br J Cancer. 2006-7-17

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

推荐工具

医学文档翻译智能文献检索